Onyvax finds potential cancer vacc efficacy test

Onyvax, a UK biotechnology company, has discovered an immunological profile that could be used to predict whether a patient will respond to cancer vaccine therapy.

This profile, which was discovered as part of a collaboration with the John van Geest Cancer Research Centre based at Nottingham Trent University, could be used to streamline the development of cancer vaccines by targeting those patients who may be more likely to respond.

Research undertaken as part of the program found significant differences in pre-treatment immunological biomarkers in patients who responded to vaccination compared to those who did not.